Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay H Traverse

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
American Heart Journal|December 11, 2019
Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarctionDan Yang, Connor Galen O'Brien, Gentaro Ikeda, et al.
Minnesota Medicine|February 14, 2008
Emerging therapies for refractory anginaDaniel Satran, Jay H Traverse, Gregory W Barsness, et al.
The American Journal of Cardiology|June 17, 2020
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry)Katelyn M Storey, Julia Wang, Ross F Garberich, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 7, 2018
Revascularization in "no option" patients with refractory angina: Frequency, etiology and outcomesRahul Sharma, Michael Tradewell, Louis P Kohl, et al.
American Heart Journal|May 28, 2018
The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study designAmish N Raval, Thomas D Cook, Henricus J Duckers, et al.
Stem Cells Translational Medicine|June 13, 2020
CD34<sup>+</sup> cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory anginaGrace L Johnson, Timothy D Henry, Thomas J Povsic, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 9, 2022
Increasing myocardial edema is associated with greater microvascular obstruction in ST-segment elevation myocardial infarctionNicole L Bonfig, Chase R Soukup, Ananya A Shah, et al.
Circulation Research|August 22, 2014
Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathyTimothy D Henry, Jay H Traverse, Baron L Hammon, et al.
Journal of Cardiovascular Translational Research|December 8, 2010
Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarctionSantiago Garcia, Timothy D Henry, Yale L Wang, et al.
Circulation|January 7, 2014
ST-elevation myocardial infarction diagnosed after hospital admissionRoss F Garberich, Jay H Traverse, Michael T Claussen, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
American Heart Journal|December 11, 2019
Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarctionDan Yang, Connor Galen O'Brien, Gentaro Ikeda, et al.
Minnesota Medicine|February 14, 2008
Emerging therapies for refractory anginaDaniel Satran, Jay H Traverse, Gregory W Barsness, et al.
The American Journal of Cardiology|June 17, 2020
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry)Katelyn M Storey, Julia Wang, Ross F Garberich, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 7, 2018
Revascularization in "no option" patients with refractory angina: Frequency, etiology and outcomesRahul Sharma, Michael Tradewell, Louis P Kohl, et al.
American Heart Journal|May 28, 2018
The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study designAmish N Raval, Thomas D Cook, Henricus J Duckers, et al.
Stem Cells Translational Medicine|June 13, 2020
CD34<sup>+</sup> cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory anginaGrace L Johnson, Timothy D Henry, Thomas J Povsic, et al.
American Journal of Physiology. Heart and Circulatory Physiology|September 9, 2022
Increasing myocardial edema is associated with greater microvascular obstruction in ST-segment elevation myocardial infarctionNicole L Bonfig, Chase R Soukup, Ananya A Shah, et al.
Circulation Research|August 22, 2014
Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathyTimothy D Henry, Jay H Traverse, Baron L Hammon, et al.
Journal of Cardiovascular Translational Research|December 8, 2010
Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarctionSantiago Garcia, Timothy D Henry, Yale L Wang, et al.
Circulation|January 7, 2014
ST-elevation myocardial infarction diagnosed after hospital admissionRoss F Garberich, Jay H Traverse, Michael T Claussen, et al.
Pageof 10